Before the opening bell, Nutra
Pharma Corporation (OTCQB: NPHC) announced a key expansion of personnel, naming
Thomas W. Northrop as its senior commercial development officer. Northrop is a
Fellow of the American College of Healthcare Executives with experience leading
hospitals, healthcare networks and physician groups in several regions of the
country. He is also a member of Tri-State Capital Partners, LLC, a New
York-based management advisory and investment firm offering combined management
resources, strategy development and implementation and capital funding
expertise to promising businesses. As a member of the Nutra Pharma management
team, Northrop will lead new marketing efforts in healthcare, governmental and
military entities; aging athletes; and the elderly, as well as playing a key
role in the completion of scientifically rigorous pain relief trials in
multiple settings.
“The addition of Tom Northrop and
Tri-State’s arrival as part of Nutra Pharma’s expanded management team are the
first steps in the company’s growth strategy for 2016,” Rik J. Deitsch, chief
executive officer of Nutra Pharma, stated in the news release. “Tri-State
believes, as we do, that Nutra Pharma has a powerful set of products that
effectively combat chronic – often debilitating – pain, without the damaging
side effects common to other treatments. We have been working closely over the
last few months and they are now committed to helping us achieve our growth
goals.”
In 2012, health care providers
throughout the United States wrote 259 million prescriptions for opioid
painkillers, according to a report by the Centers for Disease Control and
Prevention (http://dtn.fm/zqY9A), equating to roughly twice the number of painkiller
prescriptions per person written in neighboring Canada. As opioid abuse
continues to emerge as a growing cause for concern throughout the country,
Nutra Pharma’s innovative pain relief solutions, which are non-opiate,
non-narcotic and non-addictive, strategically position the company to address
an expansive global market while simultaneously promoting sustainable financial
growth.
“With opioid abuse at record
levels, and increased recognition of the dangers of misusing acetaminophen and
non-steroidal anti-inflammatory drugs (NSAID) like ibuprofen, Nutra Pharma is
well positioned to help an enormous global market, and to reap the associated
rewards,” added Northrop.
Nutra Pharma is currently
marketing both Nyloxin® and Pet Pain-Away in the over-the-counter pain
management market. Nyloxin is available as both an oral spray and a topical gel
and is specifically formulated to treat back pain, neck pain, headaches, joint
pain, migraines, arthritis pain, pain from repetitive stress and neuralgia. Pet
Pain-Away is an all-natural, anti-inflammatory analgesic pain relief targeting
conditions that cause chronic pain in animals.
The company is also developing
treatments for multiple sclerosis (MS), human immunodeficiency virus (HIV),
adrenomyeloneuropathy and pain. In a letter to shareholders released in
December, Deitsch highlighted Nutra Pharma’s recent progress toward promoting
market growth – including the reception of orphan status for RPI-78M for the
treatment of pediatric MS and submittal of an additional application for orphan
status for the treatment of myasthenia gravis.
For more information on the
company, visit www.NutraPharma.com
About QualityStocks
QualityStocks is committed to connecting subscribers with
companies that have huge potential to succeed in the short and long-term
future. We offer several ways for investors to find, evaluate, and learn more
about investing in these companies.
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment